We Claim:

1. A pharmaceutical composition comprising:

(a) an anticholinergic selected from glycopyrronium bromide or an ester of a bi- or tricyclic amino alcohol of formula (I)



(I),

wherein:

Q is one of the groups $-CH_2-CH_2-$, -CH=CH-, or



,

R is methyl, ethyl, or propyl optionally substituted by fluorine or hydroxy,

R' is methyl, ethyl, or propyl, and

an equivalent of an anion X counters the positive charge of the N atom; and

Z is one of the groups



,

wherein:

Y is a single bond or an O atom,

R^1 is hydrogen, hydroxy, methoxy, ethoxy, propoxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, or hydroxypropyl,

R^2 is a thienyl, phenyl, or cyclohexyl group, wherein these groups are optionally substituted by methyl, and thienyl and phenyl are optionally substituted by fluorine or chlorine, and

R^3 is hydrogen, or a thienyl or phenyl group which is optionally substituted by fluorine, chlorine, or methyl; and

(b) a betamimetic selected from the group consisting of: formoterol; salmeterol; 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulfonyl}ethyl]amino}ethyl]-2(3*H*)-benzothiazolone; 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*N*,*N*-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*n*-butyloxyphenyl)-2-methyl-2-propylamino]ethanol; and 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino}ethanol, and a pharmacologically compatible acid addition salt thereof.

2. The pharmaceutical composition according to claim 1, wherein the anticholinergic is an ester of a bi- and tricyclic amino alcohol of formula (I)



(I),

wherein:

Q is one of the groups $-CH_2-CH_2-$, -CH=CH-, or



,

R is methyl or ethyl,

R' is methyl, and

anion X is bromide; and

Z is one of the groups



,

wherein:

R^1 is hydrogen, hydroxy, or hydroxymethyl,

R^2 is a thienyl, phenyl, or cyclohexyl group, and

R^3 is hydrogen, or a thienyl or phenyl group.

3. The pharmaceutical composition according to claim 1, wherein the anticholinergic is a salt of tiotropium.

4. The pharmaceutical composition according to claim 1, wherein the anticholinergic is tiotropium bromide.

5. The pharmaceutical composition according to claim 1, wherein the betamimetic is formoterol or salmeterol, or a pharmacologically compatible acid addition salt thereof

6. The pharmaceutical composition according to claim 1, wherein the anticholinergic is tiotropium bromide and the betamimetic is formoterol, or a pharmacologically compatible acid addition salt thereof.

7. The pharmaceutical composition according to claim 1, wherein the anticholinergic is tiotropium bromide and the betamimetic is salmeterol, or a pharmacologically compatible acid addition salt thereof.

8. The pharmaceutical composition according to claim 1, wherein the anion X is selected from the group consisting of: chloride, bromide, and methanesulfonate,

9. The pharmaceutical composition according to one of claims 1 to 8, wherein the pharmaceutical composition is an inhaled pharmaceutical composition.

10. A process for the production of a pharmaceutical composition according to one of claims 1 to 8, comprising:

(a) mixing the anticholinergic and the betamimetic; and optionally

(b) adding an adjuvant and/or carrier materials.

11. A method of treating respiratory ailments by administering to a host in need of such treatment a pharmaceutical composition according to one of claims 1 to 9.

12. The method according to claim 11, wherein the respiratory ailment is asthma or COPD.

13. A method of treating respiratory ailments by administering to a host in need of such treatment a pharmaceutical composition according to claim 9.

14. The method according to claim 13, wherein the respiratory ailment is asthma or COPD.